NIVDIREC Trademark

Trademark Overview


On Wednesday, November 25, 2020, a trademark application was filed for NIVDIREC with the United States Patent and Trademark Office. The USPTO has given the NIVDIREC trademark a serial number of 90341739. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, June 18, 2024. This trademark is owned by Bristol-Myers Squibb Company. The NIVDIREC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
nivdirec

General Information


Serial Number90341739
Word MarkNIVDIREC
Filing DateWednesday, November 25, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, June 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 9, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, January 30, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Saturday, November 28, 2020NEW APPLICATION ENTERED
Saturday, January 30, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 23, 2021ASSIGNED TO EXAMINER
Thursday, April 1, 2021NON-FINAL ACTION WRITTEN
Thursday, April 1, 2021NON-FINAL ACTION E-MAILED
Thursday, April 1, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 30, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 30, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 1, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 4, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 20, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 9, 2021PUBLISHED FOR OPPOSITION
Tuesday, November 9, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 4, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, June 29, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, June 29, 2022SOU EXTENSION 1 FILED
Wednesday, June 29, 2022SOU EXTENSION 1 GRANTED
Friday, July 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 4, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, January 4, 2023SOU EXTENSION 2 FILED
Wednesday, January 4, 2023SOU EXTENSION 2 GRANTED
Friday, January 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 28, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, June 28, 2023SOU EXTENSION 3 FILED
Wednesday, June 28, 2023SOU EXTENSION 3 GRANTED
Friday, June 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 2, 2024SOU EXTENSION 4 FILED
Tuesday, January 2, 2024SOU EXTENSION 4 GRANTED
Thursday, January 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, June 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2024SOU EXTENSION 5 GRANTED
Tuesday, June 18, 2024SOU EXTENSION 5 FILED
Tuesday, January 2, 2024SOU TEAS EXTENSION RECEIVED